(Q37865121)

24 August 2017

1 reference

title

Phase II trials with toremifene in advanced breast cancer: a review (English)

1 reference

24 August 2017

phase II clinical trial

0 references

author name string

Valavaara R

series ordinal

1

1 reference

PubMed ID

2149283

24 August 2017

language of work or name

English

0 references

publication date

1 August 1990

1 reference

Breast Cancer Research and Treatment

24 August 2017

1 reference

24 August 2017

16 Suppl

1 reference

24 August 2017

S31-5

1 reference

Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat

24 August 2017

1 reference

12 December 2020

High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study

1 reference

12 December 2020

Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse

1 reference

12 December 2020

Antioestrogen therapy of pure mesenchymal tumour

1 reference

12 December 2020

Alternative mechanism of action of "anti-oestrogens" in breast cancer

1 reference

12 December 2020

A new triphenylethylene compound, Fc-1157a. I. Hormonal effects

1 reference

12 December 2020

A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

1 reference

12 December 2020

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

1 reference

12 December 2020

Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model

1 reference

12 December 2020

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

12 December 2020

Identifiers

PubMed ID

2149283

1 reference

PubMed ID

2149283